Company / Return on Assets (ROA)
BridgeBio Oncology Therapeutics, Inc. Return on Assets (ROA) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
3.9%
FY2024
5-year range
-12.5% / 3.9%
FY2023-FY2024
Trend
+131.2%
vs FY2023
Sector context
#42 of 213
Health Care
What the data says
BridgeBio Oncology Therapeutics, Inc.'s return on assets (roa) of 3.9% is higher than 80% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
3.9% in FY2024. Top quartile in the Health Care sector.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 20% in Health CareTop 20% of 213This company 3.9% Sector average -24.2%
▼
+116.2% above sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) increased 131.2% year-over-year.
- Currently 28.1pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | 3.9% | +131.2% |
| FY2023 | -12.5% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026